National Research (NRC) Stock Price, News & Analysis

Company Overview

National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty. The company also offers marketing solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient experience, employee engagement, health risk assessments, care transition, and improvement tools. Further, the company provides reputation solutions that allow healthcare organizations to share a picture of their organization and ensure that timely and relevant content informs consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.

Key Stats

• Today's Range: $18.11 to $18.61
• 50-Day Range: $17.77 to $22.86
• 52-Week Range: $17.62 to $43.49
• Volume: 87,288 shs
• Average Volume: 86,422 shs
• Market Capitalization: $441.60 million
• P/E Ratio: 16.37
• Dividend Yield: 2.59%
• Price Target: N/A
• Consensus Rating: N/A

National Research Stock Analysis - MarketRank™

National Research scored higher than 39% of companies evaluated by MarketBeat, and ranked 233rd out of 338 stocks in the business services sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for National Research.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of National Research is 16.37, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 131.81.

Price to Earnings Ratio vs. Sector

The P/E ratio of National Research is 16.37, which means that it is trading at a less expensive P/E ratio than the Business Services sector average P/E ratio of about 42.45.

Price to Book Value per Share Ratio

National Research has a P/B Ratio of 9.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.21% of the float of National Research has been sold short.

Short Interest Ratio / Days to Cover

National Research has a short interest ratio ("days to cover") of 4.1.

Change versus previous month

Short interest in National Research has recently decreased by 5.37%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

National Research pays a meaningful dividend of 2.65%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

National Research does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of National Research is 42.48%. This payout ratio is at a healthy, sustainable level, below 75%.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.21% of the float of National Research has been sold short.

Short Interest Ratio / Days to Cover

National Research has a short interest ratio ("days to cover") of 4.1.

Change versus previous month

Short interest in National Research has recently decreased by 5.37%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.19

News Sentiment

National Research has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Business Services companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for National Research this week, compared to 2 articles on an average week.

MarketBeat Follows

1 people have added National Research to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, National Research insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.00% of the stock of National Research is held by insiders.

Percentage Held by Institutions

47.26% of the stock of National Research is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NRC Stock Analysis - Frequently Asked Questions

How have NRC shares performed this year?

National Research's stock was trading at $39.56 at the beginning of the year. Since then, NRC stock has decreased by 53.2% and is now trading at $18.50.
View the best growth stocks for 2024 here.

How were National Research's earnings last quarter?

National Research Co. (NASDAQ:NRC) issued its quarterly earnings results on Friday, October, 25th. The company reported $0.24 earnings per share for the quarter. The business had revenue of $35.82 million for the quarter. National Research had a net margin of 18.78% and a trailing twelve-month return on equity of 64.43%.

Does National Research have any subsidiaries?

National Research subsidiaries include these companies: PatientWisdom Inc., The Governance Institute, and National Research Corporation Canada.

Who are National Research's major shareholders?

Top institutional shareholders of National Research include QV Investors Inc. (1.42%), Willis Investment Counsel (0.24%), US Bancorp DE (0.19%) and Creative Planning (0.15%). Insiders that own company stock include Amandla Mk Trust, Kevin R Karas and Jona S Raasch.
View institutional ownership trends.

How do I buy shares of National Research?

Shares of NRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of National Research own?

Based on aggregate information from My MarketBeat watchlists, some other companies that National Research investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Alphabet (GOOG), Netflix (NFLX), Advanced Micro Devices (AMD) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 8/06/2024
• Ex-Dividend for 10/11 Dividend: 9/27/2024
• Dividend Payable: 10/11/2024
• Today: 11/04/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 2/11/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Business Services
• Industry: Commercial physical research
• Sub-Industry: N/A
• Current Symbol: NASDAQ:NRC
• CUSIP: N/A
• CIK: 70487
• Web: www.nrchealth.com
• Phone: (402) 475-2525
• Fax: 402-475-9061
• Employees: 435
• Year Founded: 1981

Profitability

• EPS (Most Recent Fiscal Year): $1.13
• Trailing P/E Ratio: 16.35
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $30.97 million
• Net Margins: 18.78%
• Pretax Margin: 26.00%
• Return on Equity: 64.43%
• Return on Assets: 22.41%

Debt

• Debt-to-Equity Ratio: 0.64
• Current Ratio: 0.37
• Quick Ratio: 0.37

Sales & Book Value

• Annual Sales: $148.58 million
• Price / Sales: 2.97
• Cash Flow: $1.55 per share
• Price / Cash Flow: 11.91
• Book Value: $2.02 per share
• Price / Book: 9.15

Miscellaneous

• Outstanding Shares: 23,870,000
• Free Float: 23,394,000
• Market Cap: $441.12 million
• Optionable: Optionable
• Beta: 0.51